ES2310206T3 - Derivados de 1-oxa-3,9-diaza-espiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. - Google Patents

Derivados de 1-oxa-3,9-diaza-espiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. Download PDF

Info

Publication number
ES2310206T3
ES2310206T3 ES02742943T ES02742943T ES2310206T3 ES 2310206 T3 ES2310206 T3 ES 2310206T3 ES 02742943 T ES02742943 T ES 02742943T ES 02742943 T ES02742943 T ES 02742943T ES 2310206 T3 ES2310206 T3 ES 2310206T3
Authority
ES
Spain
Prior art keywords
formula
diaza
oxa
trifluoromethyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02742943T
Other languages
English (en)
Spanish (es)
Inventor
Hai-Ying Cai
Michael Patrick Dillon
Guido Galley
Annick Goergler
Sabine Kolczewski
Dawn Marie Muszynski-Barsy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2310206T3 publication Critical patent/ES2310206T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES02742943T 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-espiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. Expired - Lifetime ES2310206T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111644 2001-05-14
EP01111644 2001-05-14

Publications (1)

Publication Number Publication Date
ES2310206T3 true ES2310206T3 (es) 2009-01-01

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02742943T Expired - Lifetime ES2310206T3 (es) 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-espiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.

Country Status (17)

Country Link
US (1) US6599900B2 (https=)
EP (1) EP1390372B1 (https=)
JP (1) JP4056887B2 (https=)
KR (1) KR100618063B1 (https=)
CN (1) CN1264847C (https=)
AR (1) AR033631A1 (https=)
AT (1) ATE401333T1 (https=)
AU (1) AU2002342238B2 (https=)
BR (1) BR0209604A (https=)
CA (1) CA2447329C (https=)
DE (1) DE60227657D1 (https=)
DK (1) DK1390372T3 (https=)
ES (1) ES2310206T3 (https=)
MX (1) MXPA03010321A (https=)
PT (1) PT1390372E (https=)
WO (1) WO2002092604A1 (https=)
ZA (1) ZA200308535B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100863854B1 (ko) 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ｃｃｒ5 수용체 조절제
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
KR101355064B1 (ko) * 2005-03-03 2014-01-24 얀센 파마슈티카 엔.브이. 치환된 옥사-디아자-스피로-[5.5]-운데카논 유도체 및뉴로키닌 길항제로서의 이의 용도
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
US7470684B2 (en) * 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP2010522707A (ja) 2007-03-29 2010-07-08 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
RU2720203C1 (ru) 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
CN110198944A (zh) 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69633245T2 (de) * 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation

Also Published As

Publication number Publication date
CN1507449A (zh) 2004-06-23
CA2447329C (en) 2009-07-28
AU2002342238B2 (en) 2007-01-25
BR0209604A (pt) 2004-03-23
KR20030094405A (ko) 2003-12-11
CN1264847C (zh) 2006-07-19
MXPA03010321A (es) 2004-02-17
AR033631A1 (es) 2003-12-26
KR100618063B1 (ko) 2006-08-30
WO2002092604A1 (en) 2002-11-21
ZA200308535B (en) 2005-01-31
DK1390372T3 (da) 2008-09-15
JP2004534758A (ja) 2004-11-18
DE60227657D1 (de) 2008-08-28
EP1390372B1 (en) 2008-07-16
EP1390372A1 (en) 2004-02-25
PT1390372E (pt) 2008-08-25
JP4056887B2 (ja) 2008-03-05
ATE401333T1 (de) 2008-08-15
US20030004163A1 (en) 2003-01-02
US6599900B2 (en) 2003-07-29
CA2447329A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
CN115279370B (zh) 用于brd9的靶向降解的化合物
ES2282794T3 (es) Composicion farmaceutica.
ES2296761T3 (es) Derivados de 1,3,8-triaza-espiro(4.5)decan-4-oma como antagonistas receptores de neurocinina.
TW202115062A (zh) Kras突變蛋白抑制劑
ES2241891T3 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b.
CA3202355A1 (en) Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
ES2430663T3 (es) Compuestos heterocíclicos para el tratamiento de afecciones relacionadas con el estrés
ES2780699T3 (es) Amidas de piperidina fusionadas útiles como moduladores de canales iónicos
ES2392796T3 (es) Moduladores de tipo indol del receptor nicotínico de acetilcolina alfa-7
ES2310206T3 (es) Derivados de 1-oxa-3,9-diaza-espiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.
CN111278815A (zh) 戊二酰亚胺
KR20220092920A (ko) 헬리오스의 소분자 분해제 및 사용 방법
ES2238560T3 (es) Derivados de piperidina como antagonistas de neuroquinina 1.
PL192397B1 (pl) Pochodna 1-(1,2-dipodstawionej piperydynylo)-4-piperydyny, jej zastosowanie, sposób wytwarzania i kompozycja farmaceutyczna
EA013108B1 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
SI9400091A (en) Substituted pyrrolo(2,3-b)pyridine derivatives
PT1720859E (pt) Antagonistas do receptor de quimiocina
EP1740577A2 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO1999032489A1 (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO2008091021A1 (ja) ヘテロシクリデン－ｎ－（アリール）アセトアミド誘導体
CA3003559C (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
KR20020073493A (ko) 치환된 피페리딘, 당해 화합물을 함유하는 약제 및 이의제조방법
JPH0568474B2 (https=)
ES2271327T3 (es) Antagonistas heterobiciclicos de crf.
CN116685585A (zh) 一种高活性的hpk1激酶抑制剂